98288-51-8

Basic information

• Product Name: (3-Bromophenyl)-acetyl chloride ,95%
• Synonyms: (3-Bromophenyl)-acetyl chloride ,95%;Benzeneacetyl chloride, 3-broMo-;3-Bromophenylacetyl chloride
• CAS NO: 98288-51-8
• Molecular Formula: C₈H₆BrClO
• Molecular Weight: 233
• Mol File: 98288-51-8.mol
• Article Data: 46

Chemical Properties

• Flash Point: >110℃
• Appearance: /
• Density: 1.547 g/mL at 25 °C
• CAS DataBase Reference: (3-Bromophenyl)-acetyl chloride ,95%(CAS DataBase Reference)
• NIST Chemistry Reference: (3-Bromophenyl)-acetyl chloride ,95%(98288-51-8)
• EPA Substance Registry System: (3-Bromophenyl)-acetyl chloride ,95%(98288-51-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 36-39
• WGK Germany: 3
• Hazardous Substances Data: 98288-51-8(Hazardous Substances Data)

Usage

Description

(3-Bromophenyl)-acetyl chloride, 95% is a highly pure reactive acetyl chloride derivative featuring a bromine atom attached to a phenyl group. (3-Bromophenyl)-acetyl chloride ,95% is widely utilized in various chemical processes and reactions, particularly in organic synthesis and pharmaceutical research. Its high purity level ensures consistent and reliable performance in laboratory applications, making it a valuable asset for introducing acetyl groups into different chemical compounds.

Uses

Used in Organic Synthesis:
(3-Bromophenyl)-acetyl chloride, 95% is used as a reagent for organic synthesis to introduce acetyl groups into various chemical compounds. Its high purity and reactivity make it an effective tool for creating new molecules and structures with specific properties and functions.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (3-Bromophenyl)-acetyl chloride, 95% is used as a key intermediate in the development of new drugs and therapeutic agents. Its ability to introduce acetyl groups into molecules can lead to the creation of novel pharmaceutical compounds with improved efficacy, selectivity, and safety profiles.
It is crucial to handle (3-Bromophenyl)-acetyl chloride, 95% with care and follow appropriate safety protocols due to its reactive nature and potential hazards.

Upstream product

• 1878-67-7 3-Bromophenylacetic acid 
• 1711-09-7 3-bromobenzoyl chloride 
• 585-76-2 m-bromobenzoic acid 
• 14062-30-7 ethyl 2-(3-bromophenyl)acetate 
• 7023-79-2 α-diazo-m-bromoacetophenone 

Downstream Products

• 388571-13-9 3-[2-(3-bromo-phenyl)-acetylamino]-benzoic acid ethyl ester 
• 1007210-90-3 2-(3-bromophenyl)-1-(4-methylpiperazin-1-yl)ethanone 
• 1197342-26-9 3-{1-[2-(3-bromophenyl)acetyl]-4,5-dihydro-1H-pyrazol-3-yl}benzonitrile 
• 1269763-63-4 ethyl 3-{4-[(3-bromophenyl)acetyl]phenyl}propanoate 
• 1364226-31-2 2-(methoxy-(3-bromobenzyl)methylene)malononitrile 
• 1428640-42-9 C₁₅H₁₇BrN₄ 
• 956025-99-3 3-(3-bromobenzyl)-1-tert-butyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1346146-37-9 (3-bromo-phenyl)-diazo-acetic acid allyl ester 
• 1346146-35-7 (3-bromo-phenyl)-acetic acid allyl ester 

Relevant articles and documents

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.

N-Alkenylation of hydroxamic acid derivatives with ethynyl benziodoxolone to synthesizecis-enamides through vinyl benziodoxolones

The stereoselective synthesis ofcis-β-N-alkoxyamidevinyl benziodoxolones (cis-β-N-RO-amide-VBXs) fromO-alkyl hydroxamic acids in the presence of an ethynyl benziodoxolone-acetonitrile complex (EBX-MeCN) is reported herein. The reaction was performed under mild conditions including an aqueous solvent, a mild base, and room temperature. The reaction tolerated variousO-alkyl hydroxamic acids derived from carboxylic acids, such as amino acids, pharmaceuticals, and natural products. Vinyl dideuteratedcis-β-N-MeO-amide-VBXs were also synthesized using deuterium oxide as the deuterium source. Valine-derivedcis-β-N-MeO-amide-VBX was stereospecifically derivatized to hydroxamic acid-derivedcis-enamides without the loss of stereoselectivity or reduction in the deuterium/hydrogen ratio.

N-monoarylacetothioureas as potent urease inhibitors: synthesis, SAR, and biological evaluation

A urease inhibitor with good in vivo profile is considered as an alternative agent for treating infections caused by urease-producing bacteria such as Helicobacter pylori. Here, we report a series of N-monosubstituted thioureas, which act as effective urease inhibitors with very low cytotoxicity. One compound (b19) was evaluated in detail and shows promising features for further development as an agent to treat H. pylori caused diseases. Excellent values for the inhibition of b19 against both extracted urease and urease in intact cell were observed, which shows IC50 values of 0.16 ± 0.05 and 3.86 ± 0.10 μM, being 170- and 44-fold more potent than the clinically used drug AHA, respectively. Docking simulations suggested that the monosubstituted thiourea moiety penetrates urea binding site. In addition, b19 is a rapid and reversible urease inhibitor, and displays nM affinity to urease with very slow dissociation (koff=1.60 × 10?3 s?1) from the catalytic domain.